Table 3.
Treatment of patients in the acute period of stroke and outcome effects at 90 days.
| Variables | Women | Men | p-Value |
|---|---|---|---|
| Revascularization therapy (IV and/or IA), n (%) | 115 (20.6) | 96 (20.6) | 1.0 |
| HT on neuroimaginga, n (%): | 79 (14.1) | 55 (11.9) | 0.307 |
| hemorrhagic infarction, n (%) | 55 (11.0) | 37 (9.1) | 0.437 |
| parenchymal hematoma, n (%) | 24 (4.9) | 18 (4.4) | 0.874 |
| Therapy with anticoagulants after index stroke, n (%) | 399 (71.3) | 367 (78.4) | 0.01 |
| Type of anticoagulation, n (%): | |||
| LMWH | 68 (12.1) | 45 (9.6) | 0.197 |
| Oral anticoagulants (warfarin/DOA) | 196 (35.0) | 181 (38.7) | 0.22 |
| Bridging therapy (LMWH, followed by oral anticoagulants) | 135 (24.1) | 141 (30.1) | 0.03 |
| No anticoagulants at all | 161 (28.8) | 101 (21.6) | 0.009 |
| Time when anticoagulant therapy was initiated, mean ± SD, days | 6.5 ± 12.4 | 6.4 ± 11.7 | 0.902 |
| Outcome effects, n (%): | |||
| Outcome ischemic events | 46 (8.2) | 30 (6.4) | 0.284 |
| Symptomatic HT | 19 (3.4) | 18 (3.8) | 0.738 |
| Mortality at 90 days | 64 (11.6) | 47 (10.1) | 0.481 |
| Unfavorable functional outcome (mRS 3-6) at 90 days | 319 (57.7) | 191 (41.1) | <0.001 |
a
Neuroimaging performed after 24–72 h from stroke onset. DOA: direct oral anticoagulants; HT: hemorrhagic transformation (either hemorrhagic infarction or parenchymal hematoma); IA: intra-arterial revascularization therapy; IV: intravenous revascularization therapy; LMWH: low molecular weight heparin.